BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30600483)

  • 1. Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men.
    Kido A; Tamada T; Kanomata N; Yamamoto A; Miyaji Y; Nagai A; Sone T
    Jpn J Radiol; 2019 Feb; 37(2):154-164. PubMed ID: 30600483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.
    Borofsky S; George AK; Gaur S; Bernardo M; Greer MD; Mertan FV; Taffel M; Moreno V; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    Radiology; 2018 Jan; 286(1):186-195. PubMed ID: 29053402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
    Chen F; Cen S; Palmer S
    Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    Choi MH; Kim CK; Lee YJ; Jung SE
    AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
    Cristel G; Esposito A; Damascelli A; Briganti A; Ambrosi A; Brembilla G; Brunetti L; Antunes S; Freschi M; Montorsi F; Del Maschio A; De Cobelli F
    Eur J Radiol; 2019 Sep; 118():51-57. PubMed ID: 31439258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.
    Weiss J; Martirosian P; Notohamiprodjo M; Kaufmann S; Othman AE; Grosse U; Nikolaou K; Gatidis S
    Invest Radiol; 2018 Mar; 53(3):186-190. PubMed ID: 29077588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
    Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
    J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
    Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
    Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
    Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.